Introduction to the In-Vitro Diagnostic Regulation (IVDR)

This two-day seminar will clarify the requirements applicable to in-vitro diagnostic devices under the IVD Regulation (EU) 2017/746. It will highlight the major changes to responsibility and product data expectations and will review the impact to industry.

21-22 May 2019

& 19-20 Nov 2019

GBP 1,499
EUR 2,099
USD 2,338

Book now

Course Overview

The In-Vitro Diagnostic Regulation (EU) 2017/746, which came into force in May 2017 with a transition period of five years, is intended to strengthen the current approval system for in-vitro diagnostics and makes substantial changes to the existing IVD Directive (98/79/EC) legislation.

The Regulation introduces a new risk-rule classification system based on the Global Harmonization Task Force (GHTF) rules which, for the first time, takes patient impact into consideration. This will have a significant impact on all manufacturers of IVDs as about 80 per cent of all devices will now require some form of conformity assessment by a Notified Body.

This seminar will clarify the requirements applicable to in-vitro diagnostic devices under the new Regulation, highlight the major changes to responsibility and product data expectations and provide a thorough understanding of the impact on the industry.

Practical workshops over the two days will help consolidate the information provided.

Who should attend

  • Regulatory affairs personnel
  • Persons responsible for regulatory compliance
  • Quality assurance professionals
  • Those responsible for OEM/subcontractor control of IVDs
  • Economic operators, importers, distributors

Programme day one

Introduction to IVDs

  • Definition of an IVD
  • Why are IVDs regulated separately?
  • Investigating standards and their use
  • Exploring CE marking

Historical overview of the current IVD Directive (98/79/EC)

  • Examining the structure and content of the IVD Directive

Introduction to IVD Regulation (EU) 2017/746

  • How did we come from the Directive to the Regulation?
  • Main drivers for change
  • Scale of change
  • Structure and Annex

Notified Bodies

  • How has the role of the Notified Bodies changed under the IVD Regulation?
  • Conformity assessment

IVD Regulation – key changes

  • Persons responsible for regulatory compliance
  • Economic operators, importers, distributors
  • UDI
  • Software
  • Intended use/intended purpose
    (including an interactive workshop)
  • Performance evaluation
  • Clinical evidence

Compiling the technical documentation for an IVD

  • Structure and content of STED
  • Technical file vs design dossier

Labelling requirements and strategies

  • Understanding electronic Instructions for Use (e-IFUs)
  • Use of language and symbols
  • Translation requirements
  • Traceability and EUDAMED
  • UDIs

Day one wrap-up and introduction to day two

Programme day two

ISO 13485:2016

  • Introduction to ISO 13485
  • Key changes from 2012 to 2016
  • Where does it fit with IVDD & IVDR?

Risk-based classification

  • How are IVDs classified?

Workshop: Product classification

  • Discussion on the classification of example IVDs

Risk management

  • Regulatory requirements
  • ISO14971
  • Usability

Workshop: Risk management

Clinical evidence and common specifications

  • Scientific validity vs performance evaluation

Vigilance and PMS

  • Regulatory requirements
  • Incident reporting/FSCA management

Case studies: Reporting/recalls

  • PMS

Key timelines and practical considerations

  • Transition period
  • Practical tips to prepare for IVD Regulation

Discussion: Preparing a roadmap for transition

Presenters

Nancy Consterdine (21-22 May 2019)

Nancy Consterdine is a joint director in her own consultancy specialising in global regulatory affairs strategy and compliance for in vitro diagnostics and medical devices, focusing on the transition to the new IVD/Medical Device Regulations, MDSAP and ISO13485:2016.

She has over 30 years in the IVD industry and in previous roles has been responsible for designing, reviewing and maintaining regulatory frameworks for self-declared and annex II list products. Also identifying regulatory strategies around global submissions (EU, FDA, Health Canada, TGA, Russia, Latin America and China). She has a special interest in labelling and UDI requirements.

Stuart Angell (21-22 May 2019)

Stuart Angell is a joint director in his own consultancy specialising in global regulatory affairs strategy and compliance for in vitro diagnostics and medical devices focusing on the transition to the new IVD/Medical Device Regulations, MDSAP and ISO13485:2016.

He has over 15 years in the IVD industry and in previous roles has been responsible for designing, reviewing and maintaining regulatory frameworks for self-declared and annex list II products including technical documentation for EU and global submissions (FDA, Health Canada, TGA, Russia, Latin America). He has an excellent understanding of risk management, Post Market Surveillance (PMS) and vigilance.

Book now

21-22 May 2019
21-22 May 2019 Rembrandt Hotel, London GBP 1,499.00
EUR 2,099.00
USD 2,338.00
+ VAT @ 20.00%
Enrol now
19-20 Nov 2019
19-20 Nov 2019 Rembrandt Hotel, London GBP 1,499.00
EUR 2,099.00
USD 2,338.00
+ VAT @ 20.00%
Enrol now

You may also be interested in

Previous customers include...

  • Alifax SPA
  • BD
  • BD & Company
  • Beckman Coulter
  • Becton Dickinson (Pty) Ltd
  • Becton Dickinson BV
  • Becton Dickinson East Africa Limited
  • Binding Site Group Ltd
  • Biotop Medical
  • Danaher
  • Di Renzo SRL
  • Diagnostic Grifols SA
  • FUJIREBIO EUROPE
  • Fujirebio-Europe NV
  • Gentian AS
  • GlaxoWellcome Production
  • INNOGENETICS
  • Kaneka Eurogentec S.A.
  • Medical Lab Science Council of Nigeria
  • NAMSA Medvance
  • Omron Healthcare Europe BV
  • PA Consulting Group
  • Psephos Biomedica
  • R&D Systems Europe Ltd
  • Renishaw plc
  • Sestria Ltd
  • Siemens Healthineers - Laboratory Diagnostics
  • SPD Development Company Limited
  • Systagenix Wound Management
  • Vivia Biotech SL